Australia’s legal cannabis market predicted to bloom to $1.5 billion by 2025
BBS Pharmaceuticals welcomes newly appointed Head of Sales & Marketing

BBS's CEO, John Dagas

These are challenging times as the world responds to the coronavirus outbreak and sets a path to recovery.

First off, our hearts go out to anyone in our global community who may be affected by the coronavirus and we wish full recovery for those who are ill.

Like you, we have watched the rising numbers of those infected by the virus and we applaud the worldwide efforts to prevent further infections and tragic deaths.

Although the coronavirus epidemic itself was not something we could predict, as a business it is our duty to always be prepared for the unexpected and stay invested and focused on our goals, so that we can weather the tough times.

In my 25 plus years in business, I’ve seen many market storms and the lesson I have learnt is that panic is never a good ally.

Businesses that deviate from their long-term plans typically regret it later.

Here at BBS we pride ourselves in being a solid business with a strong business plan.

With this in mind and as our site in South Australia is nearing completion and our partners on our trial site in South Africa are working on the cultivation of our strains, we have been putting the finishing touches to our senior management team to ensure that we hit the ground running once these unfortunate global challenges ease.